Jinling Pharmaceutical announced that the branch company Jinling Pharmaceutical Co., Ltd. Nanjing Jinling Pharmaceutical Factory received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to approve the Phase III clinical study of oxalagolide tablets. This drug is an oral gonadotropin-releasing hormone antagonist and is mainly used to treat moderate to severe pain associated with endometriosis. This approval will not have a significant impact on the company's current business performance. The company will actively promote R&D projects and disclose progress in a timely manner.

Zhitongcaijing · 09/03/2025 09:09
Jinling Pharmaceutical announced that the branch company Jinling Pharmaceutical Co., Ltd. Nanjing Jinling Pharmaceutical Factory received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to approve the Phase III clinical study of oxalagolide tablets. This drug is an oral gonadotropin-releasing hormone antagonist and is mainly used to treat moderate to severe pain associated with endometriosis. This approval will not have a significant impact on the company's current business performance. The company will actively promote R&D projects and disclose progress in a timely manner.